Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
Prairie falcons – uncertain kinship in an uncertain climate?
Predicting the effects of climate change on species at the top trophic levels is crucial because they can...
Amelioration of Alpha-Synuclein in Parkinson's Disease through potentiated protein-protein interactions
Aggregation of misfolded alpha synuclein protein is a key feature of Parkinson's Disease (PD), which afflicts...
Understanding Avian Diversity: a genomic approach to determine the relationships of Kingfishers and their allies
Understanding biodiversity is fundamental to biology. To do so, we need to know the evolutionary tree of...
